[Form 4] TriSalus Life Sciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

TriSalus Life Sciences insider award summary: Chief Financial Officer David Patience received equity awards on 08/14/2025 consisting of 200,000 restricted stock units (RSUs) payable in common stock and an employee stock option to purchase 290,000 shares at an exercise price of $3.88 per share. Following these grants, the reporting person beneficially owns 200,000 common shares and 290,000 option shares directly. The RSUs vest in four equal annual installments beginning July 1, 2026, subject to continued service. The option vests 25% on the one-year anniversary of the July 1, 2026 vesting commencement date, with the remainder vesting monthly thereafter until fully vested, and expires on 08/13/2035.

Positive

• Alignment with shareholders: Grants are equity-based (RSUs and options), tying CFO compensation to stock performance and retention.
• Clear vesting schedules: RSUs vest in four equal annual installments and the option includes a one-year cliff then monthly vesting, supporting long-term retention.

Negative

• Potential dilution: Awards add up to 490,000 shares that could become outstanding if RSUs vest and options are exercised.
• No performance conditions disclosed: Vesting is described as service-based only, with no performance metrics indicated in this filing.

Insights

Financial Analyst

TL;DR: Officer received meaningful equity compensation that aligns incentives but creates potential dilution.

The CFO's award combines 200,000 RSUs and a 290,000-share option at $3.88, establishing a long-term compensation profile tied to share performance and continued service. Vesting schedules stagger realization through 2026 start dates and extend up to 2035 for option exercise, which supports retention. These grants are routine for senior executives and signal management alignment with shareholders; however, they increase the pool of potentially dilutive securities that could convert into common shares if vested and exercised.

Corporate Governance Expert

TL;DR: Standard executive equity grants with service-based vesting; consistent with retention practices.

The structure—RSUs payable in common stock and time-vested options—follows common governance practices to retain and incentivize senior officers. The RSU four-year annual vesting and the option's one-year cliff plus monthly vesting thereafter create multi-year retention triggers. Documentation provided includes clear vesting conditions tied to continued service; no performance conditions are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patience David

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		A		200,000(1)	A	$0	200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$3.88	08/14/2025		A		290,000		(2)	08/13/2035	Common Stock	290,000	$0	290,000	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on July 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

2. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of July 1, 2026 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.

Remarks:

	/s/ David Patience	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did TriSalus (TLSI) CFO receive on 08/14/2025?

The CFO received 200,000 RSUs payable in common stock and an employee stock option for 290,000 shares at an exercise price of $3.88.

When do the RSUs and options for TLSI's CFO vest?

RSUs vest in four equal annual installments beginning July 1, 2026. The option vests 25% on the one-year anniversary of the July 1, 2026 vesting commencement date, then 1/36th monthly thereafter.

How many shares does the reporting person beneficially own after these transactions (TLSI)?

Following the reported transactions, the reporting person beneficially owns 200,000 common shares and 290,000 option shares directly.

What is the option exercise price and expiration for the TLSI grant?

The option has an exercise price of $3.88 and an expiration date of 08/13/2035.

Are the vesting conditions for TLSI awards performance-based?

No performance conditions are disclosed in this Form 4; the RSU and option vesting described are service-based (continued service).